Peer-reviewed veterinary case report
Latanoprostene bunod lowers eye pressure in cats with glaucoma
By Yang, Vanessa Y et al.·Published in Veterinary ophthalmology·2026·Department of Surgical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma.
- Species:
- cat
Plain-English summary
A group of cats with congenital glaucoma (FCG) received two different eye drops to see if they could lower eye pressure. The drops, latanoprost and latanoprostene bunod, were tested on both normal cats and those with FCG. While both drops did lower eye pressure in the FCG cats, the reduction wasn't enough to be considered clinically significant. However, the latanoprostene bunod showed a slightly better effect compared to the other drop. If your cat has glaucoma, talk to your vet about the best treatment options available.
People also search for: cat glaucoma treatment · eye drops for cat eye pressure · congenital glaucoma in cats
Abstract
OBJECTIVE: To evaluate the effects of latanoprostene bunod on intraocular pressure (IOP) and pupil diameter (PD) in normal cats and cats with feline congenital glaucoma (FCG). ANIMALS STUDIED: Five normal and 5 FCG cats. PROCEDURES: This masked, controlled crossover study comprised a 1-day Pre-treatment phase followed by two 10-day Treatment phases, each followed by a 10-day Recovery phase. During treatment, all cats received twice daily 0.005% latanoprost (LAT) or 0.024% latanoprostene bunod (LBN) in a randomized eye. Following Recovery, the same eye was treated with the opposite drug. Contralateral eyes served as saline-treated controls. Intraocular pressure and PD measurements were performed three times daily during all study phases. Data were analyzed via constrained longitudinal data analysis models. RESULTS: Neither drug significantly reduced IOP in normal cats. In FCG cats, statistically significant reductions in mean (95% CI) IOP were observed relative to controls 4 h after LAT and LBN treatment (-5.5 mmHg [-8.4, -2.5], p < .001, -7.2 mmHg [-10.2, -4.3], p < .001, respectively). These differences represented 28.4% and 37.9% IOP reductions, respectively. Mean IOP reduction after 4 h was significantly greater with LBN treatment compared to LAT (-1.8 mmHg [-3.2, -0.4], p = .012). However, these IOP reductions were not considered clinically significant. Both drugs similarly reduced PD in normal and FCG cats. CONCLUSIONS: Transient IOP reduction was observed after topical administration of LAT and LBN in FCG cats; and mean IOP difference was statistically significantly greater in LBN-treated eyes. However, the apparent enhanced hypotensive effect of LBN is not clinically significant.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39609901/